NCT07172243 BE.Amycon Biobank & Data Registry UZ Leuven
| NCT ID | NCT07172243 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universitaire Ziekenhuizen KU Leuven |
| Condition | Amyloidosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 505 participants |
| Start Date | 2025-09-24 |
| Primary Completion | 2029-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 505 participants in total. It began in 2025-09-24 with a primary completion date of 2029-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to collect and store human body material (HBM) of patients with amyloidosis in a biobank "BE.Amycon biobank" for future research and to collect clinical data of patients with amyloidosis in a database "BE.Amycon data registry".
Eligibility Criteria
Inclusion Criteria: * Provide consent and sign informed consent form * Age 18 years or older * Diagnosis of amyloidosis (suspected or confirmed, any subtypes) * For the prospective sample collection only: newly diagnosed (any subtype) or at relapse (AL amyloidosis) Exclusion Criteria: * Not willing to sign informed consent * Not able to sign informed consent
Contact & Investigator
Michel Delforge
PRINCIPAL INVESTIGATOR
UZ Leuven Gasthuisberg
Frequently Asked Questions
Who can join the NCT07172243 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Amyloidosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07172243 currently recruiting?
Yes, NCT07172243 is actively recruiting participants. Contact the research team at michel.delforge@uzleuven.be for enrollment information.
Where is the NCT07172243 trial being conducted?
This trial is being conducted at Leuven, Belgium, Leuven, Belgium.
Who is sponsoring the NCT07172243 clinical trial?
NCT07172243 is sponsored by Universitaire Ziekenhuizen KU Leuven. The principal investigator is Michel Delforge at UZ Leuven Gasthuisberg. The trial plans to enroll 505 participants.